NCT03788603已完成1 期
An Open Label, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rogaratinib (BAY1163877) in Chinese Patients With FGFR-positive Refractory, Locally Advanced, or Metastatic Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Severity of Treatment-Emergent Adverse Events(TEAEs)
研究概览
简要总结
This study is planned to determine the safety and tolerability of rogaratinib in Chinese patients with fibroblast growth factor receptor (FGFR)-positive refractory, locally advanced, or metastatic solid tumors and to characterize the pharmacokinetics of rogaratinib in Chinese patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients ≥18 years of age on the date of signing the Main Informed Consent Form.
- •Subjects with histologically or cytologically confirmed, refractory, locally advanced, or metastatic solid tumors who are not candidates for any standard therapy, excluding primary brain or spinal tumors.
- •High FGFR1, 2, 3 or 4 mRNA expression levels based on archival or fresh tumor biopsy specimen analysis (RNAscope score of 3 or 4)
- •At least one measurable lesion outside the central nervous system according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) A lesion in a previously irradiated area is eligible and to be considered measurable disease as long as there is objective evidence of progression of the lesion prior to study enrollment. Patients with resected primary tumors who have documented metastases are eligible.
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1
- •Life expectancy of at least 3 months
- •Adequate bone marrow, liver and renal function as assessed by laboratory requirements conducted within 7 days before the first dose of rogaratinib:
- •Hemoglobin (Hb) ≥9.0 g/dL (without transfusion or erythropoietin within 4 weeks before screening)
- •Absolute neutrophil count (ANC) ≥1,500/mm3
- •Platelet count ≥100,000/mm3
- •Total bilirubin ≤1.5 times the upper limit of normal (ULN). Documented or diagnosed constitutional jaundice such as Gilbert syndrome is allowed if total bilirubin is mildly elevated (<6 mg/dL).
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times ULN (≤5 times ULN for patients with liver involvement of their cancer)
- •Alkaline phosphatase ≤2.5 times ULN (≤5 times ULN for patients with liver involvement of their cancer)
- •Amylase and lipase ≤2.5 times ULN
- •Serum creatinine ≤1.5 x ULN and glomerular filtration rate (GFR) ≥30 mL/min/1.73 m2, according to the Modified Diet in Renal Disease (MDRD) abbreviated formula
排除标准
- •Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study.
- •The following previous or concurrent cancer types might be acceptable: cervical carcinoma in situ, treated basal cell carcinoma, locally confined prostate cancer, or any cancer curatively treated >3 years before the start of rogaratinib.
- •Symptomatic brain or meningeal or spinal metastases.
- •Asymptomatic brain or meningeal or spinal metastases are acceptable if all of the following criteria are met:
- •Definitive therapy completed >6 months before the start of rogaratinib
- •No evidence of the growth of brain or meningeal or spinal metastases on an imaging test performed within 4 weeks before the start of rogaratinib
- •Clinically and radiologically stable with respect to the tumor at the time of study entry
- •Moderate or severe liver cirrhosis (Child-Pugh class B or C)
- •History or current evidence of altered endocrine regulation of calcium phosphate homeostasis (e.g. parathyroidectomy, parathyroid disorder, tumor lysis, tumoral calcinosis)
- •Any previous drug / procedure-related toxicity (patients with persistent alopecia, anemia, and / or hypothyroidism can be included) not recovered to National Cancer Institute's Common Terminology Criteria for Adverse Event, version 4.03 (CTCAE v4.03) Grade 0 or 1 or not recovered to baseline preceding the prior treatment
- •Current diagnosis of any retinal disorders including retinal detachment, retinal pigment epithelial detachment (RPED), serous retinopathy or retinal vein occlusion.
- •Previous treatment with anti-FGFR directed therapies (e.g. receptor tyrosine kinase inhibitors including rogaratinib or FGFR-specific antibodies)
研究组 & 干预措施
Rogaratinib (BAY1163877)
Experimental
Eligible patients will be selected based on the confirmation of high fibroblast growth factor receptor (FGFR) 1, 2, 3 or 4 mRNA expression levels in archival or fresh tumor biopsy specimens collected before the start of screening
干预措施: Rogaratinib (BAY1163877) (Drug)
结局指标
主要结局
Severity of Treatment-Emergent Adverse Events(TEAEs)
时间窗: 30 days after last dose of rogaratinib
Frequency of Treatment-Emergent Adverse Events(TEAEs)
时间窗: 30 days after last dose of rogaratinib
AUC(0-12): AUC from time zero to 12 hours p.a. after first-dose administration
时间窗: Cycle 1 Day 1 (each cycle is 21 days)
Single dose
Cmax: Maximum drug concentration in plasma after dose administration
时间窗: Cycle 1 Day 1 (each cycle is 21 days)
Single dose
Cmax,md: Cmax after multiple dosing
时间窗: Cycle 1 Day 15 (each cycle is 21 days)
Multiple dose
AUC(0-12)md: AUC(0-12) after multiple dosing
时间窗: Cycle 1 Day 15 (each cycle is 21 days)
Multiple dose
次要结局
- Phosphate levels(Within 7-14 days after the last dose of rogaratinib)
- Response rate(Within 7-14 days after the last dose of rogaratinib)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell CancerMetastatic Renal Cell CarcinomaNCT01152801Novartis Pharmaceuticals64
招募中
1 期
To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR MutationNon-small Cell Lung CancerNCT05555212Qilu Pharmaceutical Co., Ltd.72
已完成
1 期
89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSEClear Cell Renal CarcinomaNCT03556046Radboud University Medical Center10
已完成
1 期
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid MalignanciesSolid MalignanciesNCT05866354Zai Lab (Shanghai) Co., Ltd.19
进行中（未招募）
1 期
Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy SubjectsHealthyNCT06423261Zhejiang Echon Biopharm Limited100